Medcare Pharma’s Post

🔎 Dive into TIL Therapy for Metastatic Melanoma with our Roswell Park experts! Learn about AMTAGVI's (lifileucel) FDA approval and treatment protocols, discuss best practices when identifying potential patients, and listen to an interactive Q&A to help provide insight on this exciting new option for patients.🧠💡 🎧🔬 Listen here: https://lnkd.in/gRv9WdRb

A 35-year-old presents for a consultation for widespread, chronic plaque psoriasis that is recalcitrant to multiple therapies. He had an initial response to cyclosporine and MTX, but has had no response to biologics targeting TNF, IL-17A, or IL-23. He denies joint disease. He has no family history of disease. He has had multiple skin biopsies that showed an T cell predominant psoriasiform pattern without signs of malignancy. What is the best next step? Supported by independent educational grants from Janssen Biotech, Inc and UCB Don't miss this opportunity to expand your knowledge and join us at IDS 2024! Email courses@learnskin.com once you've completed this and two more microcourses for a big discount! https://bit.ly/4cuhrla #IDS2024 #IntegrativeDermatology #LearningOpportunity #ContinuingEducation

Learn from Cancer Support Community's own Rachel Saks, MSS, LSW, OSW-C and Dr. Sandra Cuellar during this informative webinar. The registration link is below!

BREAKING: The FDA has approved tislelizumab-jsgr (Tevimbra) in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). https://lnkd.in/ea-nAcSr

💼  🎥What Are Clinical Drug Trials? In this reel, we explore the basics of clinical drug trials and their significance for uveal melanoma patients. 📺 Watch now: https://lnkd.in/e464PHhy 🎁 Get your FREE webinar pass here: https://lnkd.in/eQcEKctH 💡 Stay informed—watch and share today!

📰 The US Food and Drug Administration has granted Breakthrough Therapy Designation to sacituzumab govitecan-hziy (Trodelvy®) for the treatment of adults with ES-SCLC whose disease has progressed on or after platinum-based chemotherapy, according to an announcement from Gilead Sciences, Inc. ➡️ Learn more: https://lnkd.in/g39JRn5F #SCLC #lcsm

The first drug to help people with Duchenne Muscular Dystrophy (DMD) was developed and released in 1974. As of today, there are seven FDA-approved drugs available to treat DMD, with many more in the development pipeline. RNA therapeutics, particularly Antisense Oligonucleotides (ASOs), have become front runners in addressing the disease at its source—the dystrophin gene. At Ractigen, we are pushing the boundaries even further. By leveraging RNA activation (RNAa), we are pioneering new treatment possibilities for DMD patients. Stay tuned for more updates on our progress and breakthroughs in the fight against DMD! #DMD #Duchenne #Ractigen #RNATherapeutics #RNAa #Biotechnology #HealthcareInnovation

⚡️ FGFR inhibitors are shaping the future of precision medicine in urothelial carcinoma. Recent advancements, including erdafitinib’s FDA approval and promising combination regimens, highlight their growing role in targeted therapy for biomarker-selected patients. Expanding their use to earlier stages of disease remains a key challenge. #BladderCancer #PrecisionMedicine https://buff.ly/3VomVHU

#cancerresearch #oncology #cancertreatment https://lnkd.in/ex7NfKTx The FDA has approved nanoliposomal irinotecan, 5-fluorouracil, leucovorin and oxaliplatin (NALIRIFOX) for patients with #metastatic #pancreatic #adenocarcinoma on the basis of results from the NAPOLI 3 trial, in which this four-drug regimen improved overall survival relative to a doublet regimen. Here we discuss how, in the context of prior results from the PRODIGE 4 trial testing 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (modified FOLFIRINOX), NALIRIFOX does not seem to raise the bar, but rather exposes patients and health-care systems to #financial #toxicities.

Preemptive DPYD PGx testing helps healthcare providers identify chemotherapy patients at risk of developing severe toxicity from fluoropyrimidine treatment. The chemotherapy drug fluorouracil (5-FU), or capecitabine, is commonly used for treatment of solid cancers such as breast, colorectal, lung and other malignancies. While most patients tolerate these drugs well, some patients can experience life-threatening toxicities. DPYD PGx testing is a simple and effective way to maximize the benefits of chemotherapy while minimizing the risk of severe adverse events. Read more about the benefits of DPYD testing here: https://lnkd.in/gPYcXCVY #patientsafety #DPYD #5FU #capecitabine #pgx #pharmacogenetics #precisionprescribing